Here are 10 things to know:
1. The net sales for the first quarter were $280.1 million, a 0.9 percent negative growth compared to the same period last year.
2. The net sales were negatively impacted by $12 million related to the foreign currency exchange rates compared to the same period last year.
3. The adjusted EBITDA for the first quarter was $59 million, 21.1 percent of net sales. It was a negative 1.1 percent growth when compared to last year.
4. The company’s international segment net sales was $72.2 million and excluding the negative impact of the foreign currency exchange rates, the net sales were up 6.4 percent on a sales-per-day basis.
5. The surgical implant segment had $26.9 million for net sales, up 14.4 percent on the sales per day basis.
6. The surgical implant market success was driven by strong sales from the shoulder, knee and hip products.
7. The company had cash balances of $35.7 million.
8. The available liquidity of $85.5 million under its $100 million revolving credit as of March 28, 2015.
9. The net loss was reported at $35.2 million.
10. Net loss attributable to DJO Finance is $35.5 million.
More articles on orthopedic devices:
Zimmer, NuVasive, DJO Global & more—12 device company key notes to know
Medtronic, J&J partner with IBM—6 things to know
Venture capital dollars are going to healthcare in Florida—5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
